About Thomas Mackie
Thomas Mackie is a director at Linectra.
Form D filings also name Thomas Mackie as a director at Illuminated Holdings and OnLume.
Thomas Mackie first appears on SEC filings in 2019.
Experience
This experience comes from Thomas Mackie's profile and from SEC filings. For roles taken from filings, the years are when the filings name Thomas Mackie in the role, so the role may have started earlier or lasted longer.
CO
Cosylab Current
Board Member
2021 – Present
WI
WiSolve Current
Vice Chair Board Of Directors
2018 – Present
II
International Commission on Radiation Units and Measurements (ICRU) Current
Vice Chair Board Of Directors
2015 – Present
HI
HealthMyne, Inc. Current
Chairman of Board
2015 – Present
AC
Asto CT Current
Chairman of the Board
2015 – Present
LC
Leo Cancer Care Current
Chair Of The Board Of Directors
2014 – Present
SI
SHINE Medical Technologies, Inc. Current
Board Member
2011 – Present
MR
Morgridge Institute for Research Current
Emeritus Investigator
2010 – Present
UH
UW Health
Chief Innovation Officer
2019 – 2020
BI
BioIonix
Board Member
2005 – 2020
AA
Advocacy Consortium for Entrepreneurship (ACE)
President
2014 – 2018
UM
University of Wisconsin-Madison
Professor
1987 – 2012
TO
TomoTherapy
Founder and Chairman of the Board
1997 – 2011
Key Colleagues at Startups
The people Thomas Mackie works with at each company, as listed on that company's latest Form D.
Linectra, Inc. · Form D/A, Aug 26, 2026
NS
Nathan Schumacher
Director
BW
Brandon Walker
Chief Executive Officer and director
Illuminated Holdings, Inc. · Form D/A, Apr 22, 2025
CL
Christopher Lee
Chief Financial Officer
RR
Ray Rothrock
Director
RR
Ross Radel
Executive officer
AS
Alma Sorensen
Director
FR
Frederick Robertson
Director
GP
Gregory Piefer
Executive officer and director
GG
Gordon Gunnlaugsson
Director
DK
Derek Kramer
Executive officer
JW
Jiajia Wu
Executive officer
SM
Susan Marks
Director
ES
Eric Schutt
Executive officer
BP
Benjamin Pratt
Executive officer
DN
David Newberg
Director
PR
Paul Ryan
Director
OnLume Inc. · Form D, Jan 3, 2023
KE
Kevin Eliceiri
Director
AV
Andreas Velten
Director
ML
Michael Luzich
Director
JB
James Bowman
Chief Executive Officer
AU
Adam Uselmann
Executive officer and director
BT
Benjamin Titz
Director